Pulmatrix Halts All Clinical Development, Reports $3.3M Cash and $1.2M Net Loss
PULM is trading near its 52-week low of $1.16 (7.8% above the low) on light trading volume (0.3× avg).
Summary
Pulmatrix has announced it is halting all clinical development and actively seeking to license or sell its clinical assets. The company reported $3.3 million in unrestricted cash as of March 31, 2026, and a net loss of $1.2 million for Q1 2026. This strategic pivot follows the company's Q1 2026 financial report yesterday, which disclosed a net loss of $1.172 million and included a "going concern" warning, emphasizing its reliance on a planned merger for future operations. Halting all clinical trials is a highly material negative event for a small biotech company, signaling severe financial distress and a significant departure from its core development strategy. Investors will now closely monitor the company's efforts to monetize its assets and the progress of its merger, as these are crucial for its operational continuity.
At the time of this announcement, PULM was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.16 to $9.37. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.